Stock Chart

JANX

$16.66 -2.34%
Score: 43.1 HOLD
Pro
Screener
Vol: 0.48x (vs SPY: 0.6x | vs QQQ: 0.6x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 23, 2026
Rising Wedge Bearish scenario quality 62/100
Measured-move target $16.56 (-0.6%) · apex ~32 bars ahead
Historically breaks down 72% of the time; target hit in 78% of down-breaks (n=653)
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and target are drawn on the chart below.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About JANX - Janux Therapeutics, Inc. Common Stock

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Key Statistics

Market Cap $1B

More JANX Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This JANX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track JANX's price movements with trendlines, gamma walls, and key support/resistance levels.